Partners Eisai and Biogen are moving their oral beta-secretase cleaving enzyme (BACE) inhibitor E2609 into Phase III. There they join other major biopharmas…

Editas Medicine has done a deal with gene therapy small cap Adverum to introduce genome editing into diseased retina via gene therapy vectors.

Pfizer has reconsidered its Lucentis biosimilar as competition mounts and ended a development deal with small cap Pfenex.

MEI Pharma has offloaded the global rights to its AML drug pracinostat to Helsinn in a $464 million deal.

Roche and Inovio Pharmaceuticals had hoped to develop immunotherapies to treat prostate cancer and hepatitis B when they first partnered in 2013. But now that…

Sorrento Therapeutics is creating a joint venture with South Korea’s CHA Biotech to develop chimeric antigen receptor modified cellular therapies based on…

A scant 6 months after rounding up $51 million in a Series A round, Adicet Bio has secured a 5-year deal with Regeneron Pharmaceuticals.

Small cap Advaxis has a new preclinical immuno-oncology deal with industry giant Amgen that gives it $65 million in an upfront payment and investment.